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Several advances in non-viral gene transfer technology have been reported 
over the past year. Cationic lipids have been successfully used to deliver 
genes in vivo, providing a clear alternative to recombinant viruses. In 
addition, investigators have demonstrated that direct application of DNA via 
injection or particle bombardment can be used for vaccination. Analysis of the 
mechanisms employed by viruses to invade cells has demonstrated a crucial 
role for membrane-active proteins or peptides in the entry process. Several 
non-viral systems that include membrane-active elements are now available. 
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Introduction 
Many laboratories are developing non-viral methods of 
introducing enes into mammalian cells for applica- 
tions in human gene therapy. To support hese efforts, 
there is a practical argument favoring the simplicity 
and increased safety of non-viral systems. Recombinant 
viruses are fine in the laboratory and are probably safe 
in patients, but the safety certification of these vectors 
is extremely tinm-consuming and labor intensive. Non- 
viral systems provide a great flexibility in the size and 
sequence of DNA molecules that can be delivered. A 
second argument suggests that the generation of sim- 
ple and efficient non-viral delivery systems requires 
an understanding of all the limiting steps in the DNA- 
delivery process. Learning to deliver DNA effectively to 
the target cell will teach us many things about endocy- 
tosis, membrane destabilization, viral entry and gene 
maintenance in transfected cells. 
Successful delivery of a long, slender, hydrophilic 
and polyanionic DNA molecule (of micrometer dimen- 
sions) through three lipid bilayers (the cell membrane, 
as well as the double nuclear membrane) requires a 
number of obstacles to be overcome. First, the DNA 
must avoid mechanical shearing and enzymatic degra- 
dation. Second, it must survive a transient stay in the 
extracellular environment, either ex  vivo in cell culture 
medium/serum (not harsh, and quite simple to alter) 
or in  vivo in blood (more harsh) and other body fluids 
(e.g. bile, lymph and lung fluid) with exposure to the 
defense cells of the immune system as well as to com- 
ponents of the complement system. Third, DNA com- 
plexes must bind to the target cell (and perhaps not to 
other cells) and be of an internalizable size. Fourth, the 
chemistry of the complex must both allow or enhance 
release of the DNA from entrapment in vesicles and 
enable DNA to escape endosomes or lysosomes to the 
cytosol. Fifth, once the DNA is within the cell, it must 
find its way to the nucleus. Lastly, when the DNA has 
entered the nucleus, long-lived gene expression must 
be ensured. 
In this review, we briefly discuss direct approaches 
for delivering DNA either by injection into muscle 
or by particle bombardment. In addition, we con- 
centrate on two general strategies adopted in current 
non-viral approaches to gene therapy. First, cationic 
lipid-based systems, which generate positively charged 
DNA complexes that bind target cells and contain 
lipids with membrane-destabilizing properties to fa- 
cilitate the entry of DNA into the target cell. Second, 
viral mimetic systems, which employ DNA condensed 
with conjugates containing both a ligand for cell attach- 
ment/endocytosis and an endosomolytic agent (e.g. 
adenovirus or synthetic peptides) to facilitate escape 
from the vesicle into the cytoplasm. 
Truly non-viral gene delivery devices 
A number of groups have taken a pragmatic approach 
to DNA delivery. Rather than attempt o mimic virus 
entry behavior (see below), they have analyzed the de- 
livery problem and used cationic lipid chemistry, direct 
physical methods of injection, or particle bombard- 
ment to introduce the DNA into cells. Initially, these 
approaches yielded reagents that were only useful for 
cell culture experiments, but researchers have recently 
identified several applications where these approaches 
and reagents may have useful functions in  vivo. 
Direct DNA injection and particle bombardment 
Although expression levels are probably too low for 
standard gene correction applications, direct DNA in- 
Abbreviations 
CFTR--cystic fibrosis transmembrane r gulator; ITR--internal transcribed region. 
© Current Biology Ltd ISSN 0958-1669 705 
706 Mammalian gene studies 
(a) Coml)inatlon complex 
DNA ( onderlsalion 
Transkx.lion 
t ()mplex 
(;ell binding 
domain 
MelTll)rdrle 
disrupliorl 
DNA 
1000 nm 
Condensed with 
transferrin-pLys 
or other l igand-pLys 
linked to virus 
particle 
Condensed with 
transferrin-pLys 
or other ligand-pLys 
plus pept]de 
, > 
, > 
}.f..--- ::-: -:..} 
/ ~ kigand 
/~ l f  200 nm 
> 
Condensed Endosome 
DNA\ ~ lyric peptide 
100-800 nm 
(i) Transferrin or 
other ligands 
0i) Adenovirus or 
other viruses 
(iii) pLys 
(i) Transferrin or 
other ligand 
(tt) pLys 
Virus capsJd 
Endosomolytic 
peptide 
(b) Catonlc hDd cornplex 
I.)NA condensalion 
-l-ranfectlon 
( omplex 
Cell binding 
dornain 
Membrane 
disruption 
Condensed with 
cationic lipid 
i 
+ + + +  
DNA 
> 
DNA ( ondensed on ,1 ( ore of hptcl 
+~+ + + +/  
+ + ~¢,,. ' ::.-'3 ~ ..'.i. ~, + 
., .... °... °.°. ;.- .• 
~ / + . ~ £ ' : :  .-N .":.: ..'" .-" 
+ + + + 
200~800 nm 
Excess positive 
charge 
Lipid -hDd 
interacuons 
4) 1903 Currenl ( Jp rnmn m Lholechnok)gy 
Fig. 1. The two major groups of DNA delivery reagents: (a) combination complexes and (b) cationic-lipid complexes. In each type of complex, 
the DNA is reacted with cationic reagents. This reagent serves to condense the DNA as well as to attach both cell-binding and membrane- 
disrupting activities. Abbreviations include: pLys, polylysine; s/b, streptavidin/biotin; Tf, transferrin. 
jection will be very powerful as a vaccination method, 
because low-level gene expression is sufficient (and 
perhaps beneficial) for the triggering of immune re- 
sponses [1,2",3"]. 
Lipid-based systems 
The two original cationic lipids, DOTMA [4] and DOGS 
[5,6], as well as several new variations (DC-chol [7,8], 
DMRIE [9], DORIE [9] and lipofectamine [10]) have been 
used for delivery of DNA. These lipids are designed to 
attach hydrophobic aliphatic groups to DNA using a 
head group containing one to four positive charges. 
Further analysis of these compounds suggests that 
their function in DNA delivery involves additional ac- 
tivities including the condensation of the DNA structure 
and non-specific targeting of the DNA-lipid complexes 
(which carry a net positive charge; see Fig. lb) to nega- 
tively charged (sialic acid bearing) components on the 
cell surface [11]. The inclusion of lipids such as DOPE, 
which have low hexagonal phase transition tempera- 
tures is thought o be required for the activity of these 
cationic lipids [8,12,13"]. Introduction of these destabi- 
lizing cationic lipids into the bilayer at the cell surface 
or in an endosome may be disruptive or fusogenic, 
serving a function similar to the adenovirus particle in 
adenovirus-DNA complexes (see below) that facilitates 
DNA entry into the cytoplasm. Inclusion of the cationic 
cyclic antibiotic peptide gramicidin S, which has an am- 
phipathic structure, also aids in DNA delivery [13"]. 
Successful applications of these compounds include: 
DOTMA/DOPE delivery of DNA to endothelial cells in 
washed and occluded arteries [14]; DC-chol/DOPE de- 
livery of DNA directly to tumor masses [15]; DOTMA/ 
DOPE delivery of DNA to the lung [16,17"]; and a 
surprising claim for systemic delivery of DNA via an 
intravenous route using DOTMA/DOPE [18]. 
Non-viral gene delivery devices that resemble 
viruses 
Many viruses successfully enter mammalian cells and 
have undergone many rounds of evolution to refine 
this process. If we can mimic viral entry functions with- 
out undesirable viral functions, we may have a useful 
vector. 
Receptor-mediated gene delivery with polylysine-ligand 
conjugates 
This strategy involves condensing delivered DNA with 
a polycation such as polylysine, chemically linked to 
a cell-binding ligand such as asialoorosomucoid for 
hepatocytes [19] or transferrin for dividing cells [20] 
(see Fig. la). The ligand triggers binding to the target 
cell and the DNA is internalized upon endocytosis of 
the ligand-DNA complex bound to the target receptor 
[21]. A wide variety of conjugates for receptor-mediated 
gene delivery are now available ([7,8,19,20,22-26]; see 
Table 1). 
The naive assumption is that a ligand specific for a 
certain cell type will be useful for the targeted eliv- 
ery of DNA exclusively to that particular cell type and 
no other. One problem with this assumption is that the 
strong affinity of polylysine for many cell types [27,281 
limits the targeting ability of these conjugates. A ma- 
jor barrier to receptor-mediated gene delivery is that 
most endocytosed material remains entrapped within 
the vesicles. Even so, the low (but significant) levels of 
gene delivery obtained with some of these conjugates 
in the absence of an endosomolytic activity demon- 
strates that the cell biologist's view of endocytosis as 
a tightly controlled, leak-free process is not univer- 
sally true. Alternate methods of attaching ligands to 
DNA have been developed using intercalating con- 
jugates [23,29]; however, these conjugates lack DNA 
condensation activity, which must be added separately 
[29]. 
Combination complexes 
Receptor-mediated gene delivery has improved with 
the recognition that an endosomolytic agent is required 
to release material from the endocytosis pathway and 
gain entry into the cytoplasm. Two types of delivery 
complexes have demonstrated this (see Fig. 1). The 
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1able 1. Conjugates employed recently in receptor-mediated gene 
delivery 
Ligand Receptor Target cell Reference 
Asialooroso- Hepatocytes [19] 
mucoid 
Asialoglyco- 
protein receptor 
Gal4-peptide Asialoglyco- 
protein receptor 
Trigalactosylated Asialoglyco- 
bisacridine protein receptor 
Lactosylated Asialoglyco- 
polylysine protein receptor 
Insulin Insulin receptor 
Transferrin Transferrm 
receptor 
Anti-CD3 CD3 (TCR- 
associated) 
Anti-CD4, CD4 
HIV gp120 
Anti-CD7 CD7 
Anti-Tn Tn antigen (O- 
glycosylation) 
Epidermal growth Epidermal growth 
factor 
Anti-thrombo- 
modulin 
factor receptor 
Thrombomoduhn 
Hepatocytes [22] 
Hepatocytes [23] 
Hepatocytes [24] 
Wide range [25,26] 
Even wider [2*] 
range 
T cells * 
cells * 
cells 
Cells of patients 
with a rare glyco- 
sylation disorder 
Epithelial cells 
Lung endothelial [7,8] 
cells 
Anti-lg Surface Ig B cells t 
Anti-secretory Polymeric Ig Epithelial cells 
component receptor 
Lung surfactant Variety Pulmonary cell § 
proteins A, B or C types 
*M Cotten, E Wagner, ML Birnstiel, unpublished data; **M Thurnher, 
E Wagner, K Mechler, M Cotten, unpublished data; tE Wagner, 
unpublished data; :~T Ferkol, unpublished data; §GF Ross, JE Baetz, 
TR Korfhagen, J Whitsett, unpublished data. Abbreviations include: 
HIV, human immunodeficiency virus; Ig, immunoglobulin; TCR, T-cell 
receptor. 
addition of adenovirus particles, which are naturally 
endosomolytic [30-321, enhances gene delivery [33-35] 
and is particularly effective when the DNA to be deliv- 
ered is linked directly to the exterior of the adenovirus 
particle [36]. Other, more inert, viruses can also be used 
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for this purpose: the chicken adenovirus (CELO virus) 
is naturally defective in the mammalian cell and pro- 
vides a potent endosome disruption activity [37]. In 
addition, the human rhinovirus has also been shown to 
augment DNA delivery (W Zauner, D Blaas, E Ktichler, 
E Wagner, unpublished ata). 
Gene delivery can also be enhanced by the inclusion of 
membrane-disruptive acid-stabilized amphipathic he- 
lix peptides in polylysine-DNA complexes [22,24,38°]. 
Synthetic positively-charged polyamidoamine cascade 
polymer particles (50-70 nm in size) have been found 
to possess useful DNA delivery activity when used 
in charge-excess over the delivered DNA; coupling 
the membrane-active GALA peptide [39,40] to these 
particles allows DNA delivery with charge-neutral 
polymer-DNA complexes [41°]. The genetic addition of 
endosomolytic peptides to the surface of either virus- 
like particles from yeast or self-assembling structures 
based on the bacteriophage MS2 capsid can also gen- 
erate endosomolytic elements useful for DNA delivery 
(S Chiocca, E Wagner, M Cotten, unpublished ata). 
Conclusions and future directions 
Major successes have now been achieved in attempts 
to import DNA into the cell using non-viral approaches. 
Many of these efforts have focused on methods either 
to penetrate the cytoplasmic membrane or to release 
endocytosed material into the cytoplasm. At present, 
it is unclear how DNA, once released into the cyto- 
plasm, enters the nucleus. A simple explanation could 
be that the cell has mechanisms for gathering chro- 
mosomal material into the two nascent daughter nu- 
clei after the breakdown of the nuclear envelope at 
mitosis. Cation-DNA complexes are simply included 
in this passive round-up. Efforts to include proteins 
with nuclear localization signals such as HMG proteins 
[26,42-44] or histone H4 [45] have provided modest 
improvements in DNA delivery, but nothing to sug- 
gest that a new barrier has been surmounted. The 
high efficiency of combination complexes containing 
adenovirus particles may result from the virus func- 
tioning at both the endosome-disruption step and the 
nuclear-localization step. Yet, the capacity of combi- 
nation complexes containing rhinovirus, which is a 
cytoplasmic virus, to potentiate DNA delivery argues 
against his role. 
The next challenge to be met is that of stable 
gene maintainance. If gene therapists are to advance 
medicine and provide an alternative to pharmaceu- 
ticals, then they will often need to achieve long- 
term gene expression. The exodus from the recombi- 
nant retrovirus field does not mean that these viruses 
have no future in gene therapy. A method employing 
the retroviral functions that fix introduced genes into 
the chromosomes of target cells may soon be devel- 
oped. Similarly, the adenovirus-associated virus inter- 
nal transcribed regions (ITRs) may also be exploited 
to integrate genes, possibly with the help of the viral 
replication (REP) functions. 
Acknowledgements 
We acknowledge Max Birnstiel, Susanna Chiocca and Michael 
Buschle for their useful comments on this manuscript. We thank 
Frank Szoka, Phil Feigner and Jean-Paul Behr for sharing informa- 
tion before publication. 
References and recommended reading 
Papers of particular interest, published within the annual period of 
review, have been highlighted as: 
• of special interest 
• . of outstanding interest 
1. WILLIAMS RS JOHNSTON SA, RIEDY M, DEVIT MJ, MCELLIGOTT 
SG, SANEORD JC: Introduction of Foreign Genes into Tissues 
of Living Mice by DNA-Coated Microprojectiles. Proc Natl 
Acad Set USA 1991, 88:2726-2730. 
2. TANG D, DEVIT M, JOHNSTON SA: Genetic Immunization is 
• a Simple Method for Eliciting an Immune Response. Nature 
1992, 356:152-154. 
This work, like that of Ulmer et al. [3°], demonstrates the potential 
of direct gene delivery for vaccine development. A human growth 
hormone gene under the control of a strong viral promoter is intro- 
duced into the ear skin of mice using microprojectile bombardment. 
The mice subsequently develop antibodies to the encoded protein. 
3. ULMER J, DONNELLY J, PARKER S, RHODES G, FELGNER P, 
• DWARKI V, GROMKOWSKI S, DECK R, DEWITr C, FRIEDMAN 
A, HAWE L, LEANDER K, MARTINEZ D, PERRY H, SHIVER J, 
MONTGOMERY D, LIU M: Heterologous Protection Against 
Influenza by Injection of DNA Encoding a Viral Protein. 
Science 1993, 259:1745-1749. 
Demonstrates the potential of direct gene injection for vaccine devel- 
opment (see also [2"]). A simple injection of DNA encoding the in- 
fluenza A matrix protein into muscle generates an immune response 
that protects the injected mice against challenge with influenza virus. 
4. FELGNER PL, GADEK TR, HOLM M, ROMAN R, CHAN I-IXV, WENZ 
M, NORTHROP JP, RINGOLD GM, DANIELSEN M: Lipofection: 
A Highly Efficient, Lipid-Mediated DNA Transfection Proce- 
dure. Proc Natl Acad Sci USA 1987, 84:7413-7417. 
5. BEHR JP, DEMENEIX B, LOEFFLER JP, PEREZ--MUTUL J: Efficient 
Gene Transfer into Mammalian Primary Endocrine Cells with 
Lipopolyamine-Coated DNA. Proc Nail Acad Sci USA 1989, 
86:6982--6986. 
6. DEMENEIX B, FREDRIKSSON G, LEZOUAL'CH F, DAUGERAS--BERN- 
ARD N, BEHR JP, LOEFFLER JP: Gene Transfer into Intact Ver- 
tebrate Embryos. Int J Dev Biol 1991, 35:481-484. 
7. TRUBETSKOY V, TORCHILIN V, KENNEL S, HUANG L: Use of 
N-Terminal Modified Poly(L-Lysine)-Antibody Conjugate as a 
Carrier for Targeted Gene Delivery in Mouse Lung Endothe- 
lial Cells. Bioconjugate Chem 1992, 3:323-327. 
8. TRUBETSKOY V, TORCH1LIN V, KENNEL S, HUANG L: Cationic 
Liposomes Enhance Targeted Delivery and Expression of  
Exogenous DNA Mediated by N-Terminal Modified Poly(L- 
Lysine)-Antibody Conjugate in Mouse Lung Endothelial Cells. 
Biochtm Biophys Acta 1992, 1131:311-313. 
9. FELGNER J, BENNETr F, FELGNER PL: Cationic Lipid-Mediated 
Delivery of Polynucleotidcs. Methods 1993, 5:67-75. 
10. HAWLEY-NELSON P, CICCARONE V, GEBEYEHU G, JESSEE J, 
FELGNER PL: Lipofectamine Reagent: A New Higher Effi- 
ciency Polycationic Liposome Transfection Reagent. Focus 
1993, 15:73-78. 
11. BEHR JP: Synthetic Gene Transfer Vectors. Accounts Chem 
Res 1993, in press. 
12. ELLENS H, BENTZ J, SZOKA FC: Destabilization of Phos- 
phatidylethanoloamine Liposomes at the Hexagonal Phase 
Transition Temperature. Biochemistry 1986, 25:285-294. 
13. LEGENDRE JY, SZOKA FC: Cyclic Amphipathic Peptide-DNA 
• Complexes Mediate High-Efficiency Transfection of Adherent 
Cells. Proc Natl Acad Sci USA 1993, 90:893-897. 
A careful analysis of the role of lipid structure in membrane destabi- 
lization. Also demonstrates the utility of a nlembrane-active p ptide 
for enhancing DNA delivery. 
14. MABEL EG, WANG Z, LIPTAY S, SAN H, GORDON D, 
HAUDENSCH1LD C, MABEL GJ: Recombinant Platelet-Derived 
Growth Factor B Gene Expression in Porcine Arteries 
Induces Intimal Hyperplasia in Vivo. J Clin Invest 1993, 
91:1822-1829. 
15. PLAtYI'Z GE, YANG Z, WU B, GAO X, HUANG L, MABEL GJ: 
Immunotherapy of Malignancy by in Vivo Gene Transfer 
into Tumors. Proc Natl Acad Sci USA 1993, 90:4645-4649. 
16. STRIBLING R, BRUNETI'E E, LIGGrFT D, GAENSLER K, DEBS R: 
Aerosol Gene Delivery in Vivo. Proc Natl Acad Sci USA 
1992, 89:11277-11281. 
17. HYDE S, GILL D, HIGGINS C, TREZISE A, MACVINISH L, 
• CUTHBERT A, RATLIFF R, EVANS M, COLLEDGE W: Correction 
of the Ion Transport Defect in Cystic Fibrosis Transgenic 
Mice by Gene Therapy. Nature 1993, 362:250-255. 
Several new deve lopments - - the  availability of the cystic fibrosis 
transmembrane regulator (CFTR) gene, gene-knockout cystic fibro- 
sis mice, and in vivo cationic lipid-DNA del ivery--  are combined 
to demonstrate he feasibility of genetic orrection of cystic fibrosis. 
18. ZHU N, LIGGITI" D, LIU Y, DEBS R: Systemic Gent  Expression 
After Intravenous DNA Delivery into Adult Mice. Science 
1993, 261:209-211. 
19. Wu GY, Wu CH: Receptor-Mediated in Vitro Gene Trans- 
formation by a Soluble DNA Carrier System. J Biol Chem 
1987, 262: 4429-4432. 
20. WAGNER E, ZENKE M, COTrEN M, BEUG H, BIRNS'IIEL ML: 
Transferrin-Polycation Conjugates as Carriers for DNA Up- 
take into Cells. Proc Natl Acad Sct USA 1990, 87: 3410- 
3414. 
21. COl'TEN M, WAGNER E, BIRNST1EL ML: Receptor-Mediated 
Transport of DNA into Eukaryotic Cells. Methods Enzymol 
1993, 217: 618-644. 
22. PLANK C, ZATLOUKAL K, COTFEN M, MECHTLER K, WAGNER 
E: Gene Transfer into Hepatocytes using Asialoglycoprotein 
Receptor Mediated Endocytosis of DNA Complexed with 
an Artificial Tetra-Antennary Galactose Ligand. Bioconjugate 
Chem 1992, 3:533-539. 
23. HAENSLER J, SZOKA FC: Synthesis and Characterization of a 
Trigalactosylated Bisacridine Compound to Target DNA to 
Hepatocytes. Bioconjugate Chem 1993, 4:85-93. 
24. MIDOUX P, MENDES C, LEGRAND A, RAIMOND J, MAYER R, 
MONSIGNY M, ROCHE AC: Specific Gene Transfer Mediated 
by Lactosylated Poly-L-Lysine into Hepatoma Cells. Nucleic 
Acids Res 1993, 21:871-878. 
25. HUCKETr B, ARIATrl M, HAWTREY AO: Evidence for Targeted 
Gene Transfer by Receptor-Mediated Endocytosis: Stable Ex- 
pression following Insulin-Directed Entry of neo into HepG2 
Cells. Btochern Pharrnacol 1990, 40:253-263. 
26. ROSENKRANZ AA, YACHMENEV SV~ JAMS DA, SEREBRYAKOVA 
NV, MURAV'EV VI, PETERS R, SOBOLEV AS: Receptor-Mediated 
Endocytosis and Nuclear Transport of a Transfecting DNA 
Construct. Exp Cell Res 1992, 199:323-329. 
Non-viral approaches to gene therapy Cotten and Wagner 709 
27. LEONEI'I'I JP, RAYNER B, LEMAITRE M, GAGNOR C, MILHAUD 
PG, IMBACH J, LEBLEU B: Antiviral Activity of Conjugates 
between Poly(L-Lysine) and Synthetic Oligodeoxyribonu- 
cleotides. Gene 1988, 72:323-332. 
28. SHEN W~ RYSER HJP: Conjugation of Poly-L-Lysine to Albumin 
and Horseradish Peroxidase: A Novel Method of Enhancing 
the Cellular Uptake of Proteins. Proc Natl Acad Sci USA 
1978, 75:1872-1876. 
29. WAGNER E, COTFEN M, MECHTLER K, K1RLAPPOS H, BIRNSTIEL 
ML: DNA-Binding Transferrin Conjugates as Functional Gene- 
Delivery Agents: Synthesis by Linkage of Polylysine or Ethid- 
ium Homodimer to the Transferrin Carbohydrate Moiety. 
Bioconjugate Chem 1991, 2:226-231. 
30. FITZGERALD D, PADMANABHAN R, PASTAN I, WILLINGHAM M: 
Adenovirus-Induced Release of  Epidermal Growth Factor 
and Pseudomonas Toxin into the Cytosol of KB Cells during 
Receptor-Mediated Endocytosis. Cell 1983, 32:607-617. 
31 SETH P, PASTAN I, WILLINGHAM M: Adenovirus-Dependent in- 
crease in Cell Membrane Permeability. J Biol Chem 1985, 
260:9598--9602. 
32. BLUMENTHAL R, SETH P, WILLINGHAM M, PASTAN I: pH-Depen- 
dent Lysis of Liposomes by Adcnovirus. Biochemistry 1986, 
25:2231-2237. 
33. CURIEL DT, AGARWAL S, WAGNER, E, CO'ITEM M: Adenovirus 
Enhancement of Transferrin-Polylysine Mediated Gene De- 
livery. Proc Natl Acad Sci USA 1991, 88:8850-8854. 
34. COTFEN M, WAGNER E, ZATLOUKAL K, PHILLIPS S, CURIEI. 
D, BIRNSIlEL ML: High-Efficiency Receptor-Mediated Deliv- 
ery of Small and Large (48 kb) Gene Constructs using the 
Endosome-Disruption Activity of Defective or Chemically- 
Inactivated Adenovirus Particles. Proc Natl Acad Set USA 
1992, 89:6094-6098. 
35. CRISTIANO RJ, SMITH LC, WOO SLC: Hepatic Gene Therapy: 
Adenovirus Enhancement of Receptor-Mediated Gene Deliv- 
ery and Expression in Primary Hepatocytes. Proc Natl Acad 
Sci USA 1993, 90:2122-2126. 
36. WAGNER E, ZATLOUKAL K, COTYEN M, K1RLAPPOS H, MECHTLER 
K, CURIEL D, BIRNSllEL ML: Coupling of Adenovirus 
to Transferrin-Polylysine/DNA Complexes Greatly Enhances 
Receptor-Mediated Gene Delivery and Expression of Trans- 
fected Cells. Proc Natl Acad Sci USA 1992, 89:6099-6103. 
37. COTFEN M, WAGNER E, ZATLOUKAL K, BIRNST1EL ML. Chicken 
Adenovirus (CELO Virus) Particles Augment Receptor-Me- 
diated DNA Delivery to Mammalian Cells and Yield Ex- 
ceptional Levels of Stable Transformants. J virol 1993, 
67:3777-3785. 
38. WAGNER E, PLANK C, ZATLOUKAL K, COTTEN M, BIRNSTIEL ML: 
• Influenza Virus Hemagglutinin HA-2 N-Terminal Fusogenic 
Peptides Augment Gene Transfer by Transferrin-Polylysine- 
DNA Complexes: Toward a Synthetic Virus-Like Gene-Trans- 
fer Vehicle. Proc Natl Acad Sci USA 1992 89:7934-7938. 
Demonstrates the requirement for two functions in a synthetic virus; 
a ligand (transferrin coupled to polylysine) for attachment to the tar- 
get cell and an endosomolytic function (a synthetic influenza hemag- 
glutinin peptide coupled to polylysine) to gain entry into the cyto- 
plasm. 
39. SUBBARAO NK, PARENTE RA, SZOKA FC, NADASDI L, PONGRACZ 
K: pH-Dependent Bilayer Destabillzation by an Amphipathic 
Peptide. J Biol Chern 1987, 26:2964-2972. 
40. PARENTE RA, NIR S, SZOKA FC: Mechanism of Leakage 
of Phospholipid Vesicle Contents Induced by the Peptide 
GALA. Biochemistry 1990, 29:8720-8728. 
41. HAENSLER J, SZOKA FC: Polyamidoamine Cascade Polymers 
• Mediate Efficient Transfection of Cells in Culture. Btocon- 
jugate Chem 1993, 4:372-379. 
Identifies a new synthetic ationic polymer, polyamidoamine, with 
DNA delivery activity. 
710 Mammalian gene studies 
42. BOTI'GER M, VOGEL F, PLATZER M, KIESSLING U, GRADE K, 
STRAUSS M: Condensation of Vector DNA by the Chromoso- 
mal Protein HMG1 Results in Efficient Transfection. Biochim 
Biophys Acta 1988, 950: 221-228. 
43. KANEDA Y, IWAI K, UCHIDA T: Increased Expression of DNA 
Cointroduced with Nuclear Protein in Adult Rat Liver. Sci- 
ence 1989, 243:375-378. 
44. TOMITA N, H1GAKI J, MORISHITA R, KATO K, MIKAMI H, 
KANEDA Y, OGIHARA T: Direct in Vivo Gene Introduc- 
tion into Rat Kidney. Biochem Biophys Res Comm 1992, 
186:129-134. 
45. WAGNER E, COTI'EN M, FOISNER R BIRNSTIEL ML: Transferrin- 
Polycation-DNA Complexes: The Effect of Polycations on the 
Structure of the Complex and DNA Delivery to Cells. Proc 
Nail Acad Sci USA 1991, 88:4255-4259. 
M Cotten and E Wagner, Research Institute of Molecular Pathology, 
Dr Bohr-Gasse 7, A-1030 Vienna, Austria. 
